

Biography
Professional Summary
Education & Certifications
- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2013) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2013)
- Residency: University of Washington Medical Center Dept of Medicine (2010) WA
- Medical Education: University of California Davis School of Medicine (2006) CA
- Fellowship: Memorial Sloan-Kettering Cancer Center (2009) NY
- Board Certification: American Board of Internal Medicine, Hematology (2014)
Awards & Memberships
- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2018)
- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2020)
Publications
-
New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients
Gupta, N. K., & Andreadis, C. (2014). New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(10), 1371–75. -
How I treat CNS lymphomas
Rubenstein, J. L., Gupta, N. K., Mannis, G. N., LaMarre, A. K., & Treseler, P. (2013). How I treat CNS lymphomas. BLOOD, 122(14), 2318–30. -
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma
Gupta, N. K., Barker, J. N., Young, J. W., & Noy, A. (2009). Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma. LEUKEMIA & LYMPHOMA, 50(12), 2075–2077. -
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J., Olin, R. L., … Martin, T. G. (2015). Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. BONE MARROW TRANSPLANTATION, 50(1), 40–44. -
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium
Bayraktar, U. D., Ramos, J. C., Petrich, A., Gupta, N., Lensing, S., Moore, P. C., … Noy, A. (2012). Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. LEUKEMIA & LYMPHOMA, 53(12), 2383–2389. -
Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing
Martin, W. J., Gupta, N. K., Loo, C. M., Rohde, D. S., & Basbaum, A. I. (1999). Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing. PAIN, 80(1-2), 57–65. -
The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care.
Mannis, G. N., McNey, L. M., Gupta, N. K., & Gross, D. M. (2016). The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care. American Journal of Hematology. -
Diffuse Large B-cell Lymphoma
Gupta, N. K., & Kaplan, L. D. (2014). Diffuse Large B-cell Lymphoma. Cancers in People with HIV and AIDS (pp. 175–182). Springer. -
Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta, N. K., Nolan, A., Omuro, A., Reid, E. G., Wang, C.-C. C., Mannis, G., … Rubenstein, J. L. (2016). Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology. -
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364). -
Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., … Alizadeh, A. A. (2016). Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. BLOOD. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY. -
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246. -
Cancer in People Living With HIV, Version 1.2018 Clinical Practice Guidelines in Oncology
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., … Freedman-Cass, D. A. (2018). Cancer in People Living With HIV, Version 1.2018 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(8), 986–1017. -
Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., … Alizadeh, A. A. (2016). Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. BLOOD. AMER SOC HEMATOLOGY. -
Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., … Alizadeh, A. A. (2016). Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Circulating tumor DNA (ctDNA) in B-cell lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. WILEY. -
Reply to J. Wang et al.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907. -
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., … Freedman-Cass, D. A. (2019). AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(2), 171–89. -
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+. -
AIDS-Related Kaposi Sarcoma, Version 2.2019
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., … Freedman-Cass, D. A. (2019). AIDS-Related Kaposi Sarcoma, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(2), 171–89. -
Noninvasive molecular subtyping and risk stratification of DLBCL.
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Noninvasive molecular subtyping and risk stratification of DLBCL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.
Gupta, S., Long, S. R., Natkunam, Y., Kong, C. S., Gupta, N. K., & Gratzinger, D. (2020). Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma. Cancer Cytopathology. -
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium
Noy, A., Lensing, S. Y., Moore, P. C., Gupta, N., Aboulafia, D., Ambinder, R., … Chadburn, A. (2016). Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. LEUKEMIA & LYMPHOMA, 57(7), 1731–34. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
Binkley, M. S., Hiniker, S. M., Younes, S., Yoo, C., Wignarajah, A., Jin, M., … Hoppe, R. T. (2021). Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy. Leukemia & Lymphoma, 1–15. -
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery. -
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., … Gordon, L. I. (2022). Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. The Lancet. Oncology. -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G., … Gordon, L. I. (2022). Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) »
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia »
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma »
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma »
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies »
- Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. »
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas »
- Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) »
Practice Locations
Lymphoma Program Palo Alto, CA
Palo Alto, CALymphoma Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Lymphoma Program in Palo Alto Palo Alto, CA
Palo Alto, CALymphoma Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(136 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

- Send referrals online
- Place radiology orders
- View referral status
- Access medical records